reboxetine

Ligand id: 4808

Name: reboxetine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: reboxetine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 39.72
Molecular weight 313.17
XLogP 4.53
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the treatment of clinical depression, panic disorders and ADHD. There is no information regarding marketing authorisation for this drug on the US FDA or EMA websites. Other national approval agencies may have granted marketing approval. For example, the UK granted approval in 1997 for Edronax® for acute treatment of depressive illness/major depression and for maintaining clinical improvement in patients initially responding to treatment.
Mechanism Of Action and Pharmacodynamic Effects
Selectively inhibits noradrenaline reuptake. Reboxetine is also reported to inhibit brain and cardiac G protein-coupled inwardly-rectifying potassium channels (GIRKs) which may contribute to some of the therapeutic effects of NRIs and adverse side effects related to nervous system and heart function.[1].
External links